MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical-stage genetic medicines company, reported its financial results for the first quarter ending March 31, 2025. The company reported a net loss attributable to ordinary shareholders of $40.0 million, compared to a net loss of $20.4 million for the same period in 2024. The increase in net loss is reflected in the basic and diluted net loss per ordinary share, which was $0.51 in 2025 compared to $0.32 in 2024. Interest income for the quarter was $1.0 million, slightly down from $1.1 million for the same period in the previous year, due to lower interest rates and reduced cash balances. Interest expense decreased to $3.0 million from $3.2 million, primarily due to a lower interest rate related to debt financing. A notable change was observed in foreign currency gains, which amounted to $3.7 million, compared to a loss of $0.5 million in the previous year, driven by the weakening of the U.S. dollar against the pound sterling and euro. Additionally, the company did not report any gain on the sale of nonfinancial assets in the current period, compared to a significant gain of $29.0 million in the prior year, which had included a $50.0 million milestone related to an asset purchase agreement. Operationally, MeiraGTx is advancing its late-stage clinical programs and engaging with the FDA for potential expedited approval of AAV-AIPL1 for children with LCA4, based on promising data from treatments under its Specials License in the U.K. The company is continuing discussions with global regulators to support these efforts.